These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30061222)

  • 21. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer.
    Ståhlbom AK; Johansson H; Liljegren A; von Wachenfeldt A; Arver B
    Fam Cancer; 2012 Mar; 11(1):33-40. PubMed ID: 22124624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers.
    Laitman Y; Keinan Boker L; Liphsitz I; Weissglas-Volkov D; Litz-Philipsborn S; Schayek H; Friedman E
    Breast Cancer Res Treat; 2015 Apr; 150(3):631-5. PubMed ID: 25788227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
    Euhus DM; Smith KC; Robinson L; Stucky A; Olopade OI; Cummings S; Garber JE; Chittenden A; Mills GB; Rieger P; Esserman L; Crawford B; Hughes KS; Roche CA; Ganz PA; Seldon J; Fabian CJ; Klemp J; Tomlinson G
    J Natl Cancer Inst; 2002 Jun; 94(11):844-51. PubMed ID: 12048272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models.
    Roudgari H; Miedzybrodzka ZH; Haites NE
    Fam Cancer; 2008; 7(3):199-212. PubMed ID: 18097771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.
    Quante AS; Whittemore AS; Shriver T; Hopper JL; Strauch K; Terry MB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25956172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of three BRCA1/2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families.
    Schneegans SM; Rosenberger A; Engel U; Sander M; Emons G; Shoukier M
    Fam Cancer; 2012 Jun; 11(2):181-8. PubMed ID: 22160602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Report of Endometrial Cancer in Australian BRCA1 and BRCA2 mutation-positive Families.
    Duffy DL; Antill YC; Stewart CJ; Young JP; ; Spurdle AB
    Twin Res Hum Genet; 2011 Apr; 14(2):111-8. PubMed ID: 21425892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
    Terkelsen T; Christensen LL; Fenton DC; Jensen UB; Sunde L; Thomassen M; Skytte AB
    Fam Cancer; 2019 Oct; 18(4):381-388. PubMed ID: 31435815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort.
    Kwong A; Wong CH; Suen DT; Co M; Kurian AW; West DW; Ford JM
    World J Surg; 2012 Apr; 36(4):702-13. PubMed ID: 22290208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations.
    Teller P; Hoskins KF; Zwaagstra A; Stanislaw C; Iyengar R; Green VL; Gabram SG
    Ann Surg Oncol; 2010 Jan; 17(1):240-6. PubMed ID: 19763692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
    Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
    Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
    Rosenberg SM; Ruddy KJ; Tamimi RM; Gelber S; Schapira L; Come S; Borges VF; Larsen B; Garber JE; Partridge AH
    JAMA Oncol; 2016 Jun; 2(6):730-6. PubMed ID: 26867710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictability of BRCA1/2 mutation status in patients with ovarian cancer: How to select women for genetic testing in middle-income countries.
    Teixeira N; Maistro S; Del Pilar Estevez Diz M; Mourits MJ; Oosterwijk JC; Folgueira MAK; de Bock GH
    Maturitas; 2017 Nov; 105():113-118. PubMed ID: 28619461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.
    Rao NY; Hu Z; Yu JM; Li WF; Zhang B; Su FX; Wu J; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 Aug; 116(3):563-70. PubMed ID: 18807178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics.
    Varesco L; Viassolo V; Viel A; Gismondi V; Radice P; Montagna M; Alducci E; Della Puppa L; Oliani C; Tommasi S; Caligo MA; Vivanet C; Zuradelli M; Mandich P; Tibiletti MG; Cavalli P; Lucci Cordisco E; Turchetti D; Boggiani D; Bracci R; Bruzzi P; Bonelli L
    Breast; 2013 Dec; 22(6):1130-5. PubMed ID: 24011770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
    van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
    J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.